USA / 5 Rare Disease Start-Ups to Watch
Following on from our profile on five of the most promising clinical-stage biotech companies developing orphan…
PhRMA’s Stephen J. Ubl outlines two ways in which the new US presidency can help lower healthcare costs and why biopharmaceutical companies support changes to the system that can lower…
Following on from our profile on five of the most promising clinical-stage biotech companies developing orphan…
With Rare Disease Day coming up on February 28th, one of the leading organizations dedicated to serving affected…
The AAM’s Dan Leonard highlights the savings impact that generic and biosimilar have on US healthcare today and…
Dan Leonard, president and CEO of the Association for Accessible Medicines (AAM) since August 2020, outlines his key agenda priorities as head of the USA’s largest generic industry body, how the COVID-19 pandemic has altered the discussion around generics and essential medicines, and his hopes for the Biden administration AAM’s policies are consistent with this administration’s agenda. We have…
Dan Leonard, president and CEO of the Association for Accessible Medicines (AAM) since August 2020, outlines his…
Hours after President Biden was inaugurated on Tuesday 19th January 2021, Dr Janet Woodcock was named as acting…
A Tale of Two Americas The US stands as the biopharma innovation champion of the world, a global leader on nearly…